Clinical Trial Update: Effect of Two Doses of Olmesartan Medoxomil and Amlodipine on Vascular Markers in Hypertensive Patients With Metabolic Syndrome [Phase 3]

View source ↗

Summary

Phase 3 trial evaluating two doses of olmesartan medoxomil and amlodipine on vascular markers in patients with hypertension and metabolic syndrome has completed…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Hypertension
• Metabolic Syndrome

Drugs mentioned

• Amlodipine (amlodipine)
• OLMESARTAN MEDOXOMIL (olmesartan medoxomil)

Snippet

Sponsor: Daiichi Sankyo Europe, GmbH, a Daiichi Sankyo Company | Conditions: Metabolic Syndrome, Hypertension | Phase 3 | Status: COMPLETED